How to buy Arcellx stock in Canada

Arcellx is a biotechnology business based in the US. Arcellx shares (ACLX) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $75.54 – a decrease of 9.86% over the previous week. Arcellx employs 130 staff and has a trailing 12-month revenue of around $155.8 million.

Our top picks for where to buy Arcellx stock

Buy Arcellx stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Arcellx stock price (NASDAQ: ACLX)

Use our graph to track the performance of ACLX stocks over time.

Arcellx stocks at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$75.54
52-week range	$47.88 - $107.37
50-day moving average more info button	$88.94
200-day moving average more info button	$68.96
Wall St. target price	$116.38
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.71

Is it a good time to buy Arcellx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Arcellx price performance over time

Historical closes compared with the close of $75.54 from 2024-12-20

1 week (2024-12-13)	-9.86%
1 month (2024-11-22)	-16.48%
3 months (2024-09-20)	-12.78%
6 months (2024-06-21)	34.60%

1 year (2023-12-22)	40.28%
2 years (2022-12-22)	136.28%
3 years (2021-12-18)	N/A
5 years (2019-12-18)	N/A

Arcellx financials

Revenue TTM	$155.8 million
Gross profit TTM	$0
Return on assets TTM	-6.29%
Return on equity TTM	-10.79%
Profit margin	-25.94%
Book value	$8.95
Market Capitalization more info button	$4.1 billion

TTM: trailing 12 months

Arcellx stock dividends

We're not expecting Arcellx to pay a dividend over the next 12 months.

Arcellx stock price volatility

Over the last 12 months, Arcellx's stocks have ranged in value from as little as $47.88 up to $107.3699. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcellx's is 0.265. This would suggest that Arcellx's stocks are less volatile than average (for this exchange).

Arcellx overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Arcellx is owned by insiders or institutions?
Currently 12.623% of Arcellx stocks are held by insiders and 94.863% by institutions. How many people work for Arcellx?
Latest data suggests 130 work at Arcellx. When does the fiscal year end for Arcellx?
Arcellx's fiscal year ends in December. Where is Arcellx based?
Arcellx's address is: 800 Bridge Parkway, Redwood City, CA, United States, 94065 What is Arcellx's ISIN number?
Arcellx's international securities identification number is: US03940C1009

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.